ProRelix Research

Executive Summary

ProRelix Research is a full-service Clinical Research Organization (CRO) headquartered in Mumbai, India, with operations spanning India, the USA, and Europe. Founded in 2020, the company employs 200–500 staff and offers end-to-end clinical trial services including Phase I–IV studies, data management, medical writing, and regulatory support. ProRelix differentiates itself through AI-driven analytics and decentralized trial platforms, targeting therapeutic areas such as oncology, respiratory, ophthalmology, endocrinology, immunology, dermatology, stem cell therapy, medical devices, nutraceuticals, and herbal medicine. As a platform-stage private company, ProRelix serves pharmaceutical, biotech, and medical device clients globally. While specific financials are not disclosed, the company's focus on innovative trial technologies and broad therapeutic coverage positions it competitively in the growing CRO market. Key strengths include its AI-enabled efficiency, decentralized trial capabilities, and ability to support complex studies across multiple geographies. However, as a relatively young CRO, it faces intense competition from larger, established players. The company's progress in securing new contracts and expanding its technology platform will be critical for future growth.

Upcoming Catalysts (preview)

• Q3 2026Major Client Win or Strategic Partnership with a Top Pharma Company60% success
• Q4 2026Launch of Next-Generation AI Decentralized Trial Platform70% success
• TBDRegulatory Accreditation Expansion (e.g., USFDA or EMA inspection pass)50% success